This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanati, H.
Right arrow Articles by Ghannoum, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanati, H.
Right arrow Articles by Ghannoum, M.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., Nov 1997, 2492-2496, Vol 41, No. 11
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

H Sanati, P Belanger, R Fratti and M Ghannoum
Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California 90509, USA.

Voriconazole (UK-109,496) is a novel triazole derivative with potent broad-spectrum activity against various fungi, including some that are inherently resistant to fluconazole, such as Candida krusei. In this study we compared the effect of subinhibitory concentrations of voriconazole and fluconazole on sterol biosynthesis of fluconazole- resistant and -susceptible Candida albicans strains, as well as C. krusei, in an effort to delineate the precise mode of action of voriconazole. Voriconazole MICs ranged from 0.003 to 4 microg/ml, while fluconazole MICs ranged from 0.25 to >64 microg/ml. To investigate the effects of voriconazole and fluconazole on candidal sterols, yeast cells were grown in the absence and presence of antifungals. In untreated C. albicans controls, ergosterol was the major sterol (accounting for 53.6% +/- 2.2% to 71.7% +/- 7.8% of the total) in C. albicans and C. krusei strains. There was no significant difference between the sterol compositions of the fluconazole-susceptible and - resistant C. albicans isolates. Voriconazole treatment led to a decrease in the total sterol content of both C. albicans strains tested. In contrast, exposure to fluconazole did not result in a significant reduction in the total sterol content of the three candidal strains tested (P > 0.5). Gas-liquid chromatographic analysis revealed profound changes in the sterol profiles of both C. albicans strains and of C. krusei in response to voriconazole. This antifungal agent exerted a similar effect on the sterol compositions of both fluconazole- susceptible and -resistant C. albicans strains. Interestingly, a complete inhibition of ergosterol synthesis and accumulation of its biosynthetic precursors were observed in both strains treated with voriconazole. In contrast, fluconazole partially inhibited ergosterol synthesis. Analysis of sterols obtained from a fluconazole-resistant C. albicans strain grown in the presence of different concentrations of voriconazole showed that this agent inhibits ergosterol synthesis in a dose-dependent manner. In C. krusei, voriconazole significantly inhibited ergosterol synthesis (over 75% inhibition). C. krusei cells treated with voriconazole accumulated the following biosynthetic intermediates: squalene, 4,14-dimethylzymosterol, and 24- methylenedihydrolanosterol. Accumulation of these methylated sterols is consistent with the premise that this agent functions by inhibiting fungal P-450-dependent 14alpha-demethylase. As expected, treating C. krusei with fluconazole minimally inhibited ergosterol synthesis. Importantly, our data indicate that voriconazole is more effective than fluconazole in blocking candidal sterol biosynthesis, consistent with the different antifungal potencies of these compounds.


This article has been cited by other articles:

  • Lau, D., Fedinands, M., Leung, L., Fullinfaw, R., Kong, D., Davies, G., Daniell, M. (2008). Penetration of Voriconazole, 1%, Eyedrops Into Human Aqueous Humor: A Prospective Open-Label Study. Arch Ophthalmol 126: 343-346 [Abstract] [Full Text]  
  • Bopp, L. H., Baltch, A. L., Ritz, W. J., Michelsen, P. B., Smith, R. P. (2006). Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.. J Med Microbiol 55: 865-870 [Abstract] [Full Text]  
  • Tintillier, M., Kirch, L., Goffin, E., Cuvelier, C., Pochet, J.-M. (2005). Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 20: 664-665 [Full Text]  
  • Xiong, Q., Hassan, S. A., Wilson, W. K., Han, X. Y., May, G. S., Tarrand, J. J., Matsuda, S. P. T. (2005). Cholesterol Import by Aspergillus fumigatus and Its Influence on Antifungal Potency of Sterol Biosynthesis Inhibitors. Antimicrob. Agents Chemother. 49: 518-524 [Abstract] [Full Text]  
  • Gao, H., Pennesi, M. E., Shah, K., Qiao, X., Hariprasad, S. M., Mieler, W. F., Wu, S. M., Holz, E. R. (2004). Intravitreal Voriconazole: An Electroretinographic and Histopathologic Study. Arch Ophthalmol 122: 1687-1692 [Abstract] [Full Text]  
  • Munayyer, H. K., Mann, P. A., Chau, A. S., Yarosh-Tomaine, T., Greene, J. R., Hare, R. S., Heimark, L., Palermo, R. E., Loebenberg, D., McNicholas, P. M. (2004). Posaconazole Is a Potent Inhibitor of Sterol 14{alpha}-Demethylation in Yeasts and Molds. Antimicrob. Agents Chemother. 48: 3690-3696 [Abstract] [Full Text]  
  • Mukherjee, P. K., Chandra, J., Kuhn, D. M., Ghannoum, M. A. (2003). Mechanism of Fluconazole Resistance in Candida albicans Biofilms: Phase-Specific Role of Efflux Pumps and Membrane Sterols. Infect. Immun. 71: 4333-4340 [Abstract] [Full Text]  
  • Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., Wood, N. (2003). THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN. Drug Metab. Dispos. 31: 731-741 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., Kleinermans, D. (2002). Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens. Antimicrob. Agents Chemother. 46: 2546-2553 [Abstract] [Full Text]  
  • REIS, A., SUNDMACHER, R., TINTELNOT, K., AGOSTINI, H., JENSEN, H. E., ALTHAUS, C. (2000). Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 84: 928d-928 [Full Text]  
  • Ghannoum, M. A., Rice, L. B. (1999). Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clin. Microbiol. Rev. 12: 501-517 [Abstract] [Full Text]  
  • Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., Kwon-Chung, K. J. (1999). Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43: 1856-1861 [Abstract] [Full Text]  
  • Koul, A., Vitullo, J., Reyes, G., Ghannoum, M. (1999). Effects of voriconazole on Candida glabrata in vitro. J Antimicrob Chemother 44: 109-112 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»